Ardelyx Inc. is a biopharmaceutical company based in Fremont, California, dedicated to the development of innovative therapies targeting kidney and cardiorenal diseases. With a strong focus on renal pharmacology, the company is advancing a robust pipeline that addresses significant unmet medical needs in these areas. Through strategic partnerships and a commitment to improving patient outcomes, Ardelyx is well-positioned to deliver transformative treatments that enhance the quality of life for individuals affected by complex renal conditions. Its cutting-edge research and commitment to addressing pressing healthcare challenges underlie the company's potential for substantial growth and impact in the biopharmaceutical sector. Show more

Location: 400 FIFTH AVENUE, WALTHAM, MA, UNITED STATES, 02451, Waltham, MA, 02451, USA | Website: https://www.ardelyx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.868B

52 Wk Range

$3.21 - $8.40

Previous Close

$7.69

Open

$7.72

Volume

2,651,365

Day Range

$7.67 - $8.02

Enterprise Value

1.862B

Cash

42.72M

Avg Qtr Burn

N/A

Insider Ownership

2.95%

Institutional Own.

69.71%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
XPHOZAH (Tenapanor) (Phosphate Absorption Inhibitor) Details Electrolyte disorder, Hyperphosphatemia, Kidney disease, Chronic kidney disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tenapanor (Ibsrela) (NHE3 sodium transport inhibitor) Details Irritable bowel syndrome, Constipation	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IBSRELA/Tenapanor (NHE3 Inhibitor) Details Chronic Idiopathic Constipation	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RDX10531 (NHE3 Inhibitor) Details Multiple Therapeutic Areas	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RDX013 Details Hyperkalemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.